Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing, China; Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing, China.
Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing, China.
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):945-956. doi: 10.1016/j.ijrobp.2018.04.007. Epub 2018 Apr 16.
To evaluate the therapeutic effects of decorin (DCN)-modified mesenchymal stem cells (MSCs) on radiation-induced lung injuries (RILIs) and to clarify the underlying mechanisms.
Umbilical cord-derived mesenchymal stem cells (MSCs) were modified with Ad(E1-).DCN to generate DCN-expressing MSCs (DCN-modified MSCs [MSCs.DCN]). In an experimental mouse model of RILI, MSCs.DCN and MSCs.Null [MSCs modified with Ad(E1-).Null] were intravenously engrafted at 6 hours or 28 days after irradiation. The therapeutic effects on lung inflammation and fibrosis were evaluated by histopathologic analysis at 28 days and 3 months after irradiation. Inflammatory cytokines and chemokines were analyzed in both sera and lung tissues, and subtypes of T lymphocytes including regulatory T cells (Tregs) were analyzed in the peripheral blood and spleen.
Both MSC treatments could alleviate histopathologic injuries by reducing lymphocyte infiltration, decreasing apoptosis, increasing proliferation of epithelial cells, and inhibiting fibrosis in the later phase. However, treatment with MSCs.DCN resulted in much more impressive therapeutic effects. Moreover, we discovered that MSC treatment reduced the expression of chemokines and inflammatory cytokines and increased the expression of anti-inflammatory cytokines in both the peripheral blood and local pulmonary tissues. An important finding was that MSCs.DCN were much more effective in inducing interferon-γ expression, inhibiting collagen type III α1 expression in pulmonary tissues, and decreasing the proportion of Tregs. Furthermore, our data suggested that treatment during the acute phase (6 hours) after irradiation evoked much stronger responses both in attenuating inflammation and in inhibiting fibrosis than in the later phase (28 days).
MSCs.DCN could attenuate acute inflammation after irradiation and significantly inhibit later fibrosis. Likewise, DCN enhanced the functions of MSCs by targeting profibrotic factors and Tregs.
评估硫酸皮肤素(DCN)修饰的间充质干细胞(MSCs)对放射性肺损伤(RILIs)的治疗作用,并阐明其潜在机制。
从脐带中分离出间充质干细胞(MSCs),通过 Ad(E1-).DCN 对其进行修饰,生成 DCN 表达的 MSCs(DCN 修饰的 MSCs [MSCs.DCN])。在 RILI 的实验性小鼠模型中,在照射后 6 小时或 28 天通过静脉内移植 MSCs.DCN 和 MSCs.Null [用 Ad(E1-).Null 修饰的 MSCs]。在照射后 28 天和 3 个月通过组织病理学分析评估对肺炎症和纤维化的治疗效果。在血清和肺组织中分析炎症细胞因子和趋化因子,并在外周血和脾脏中分析调节性 T 细胞(Tregs)等 T 淋巴细胞亚群。
两种 MSC 治疗均可通过减少淋巴细胞浸润、减少细胞凋亡、增加上皮细胞增殖和抑制后期纤维化来减轻组织病理学损伤。然而,MSCs.DCN 的治疗效果更为显著。此外,我们发现 MSC 治疗可降低趋化因子和炎症细胞因子的表达,并增加外周血和局部肺组织中抗炎细胞因子的表达。一个重要的发现是,MSCs.DCN 更有效地诱导干扰素-γ的表达,抑制肺组织中胶原 III α1 的表达,并降低 Tregs 的比例。此外,我们的数据表明,在照射后急性期(6 小时)进行治疗在减轻炎症和抑制纤维化方面均比后期(28 天)产生更强的反应。
MSCs.DCN 可减轻照射后的急性炎症,并显著抑制后期纤维化。同样,DCN 通过靶向成纤维细胞因子和 Tregs 增强了 MSCs 的功能。